Naloxone Selectively Inhibits Vasoconstriction Caused by Phenylephrine but Not Endogenous Noradrenaline in the Rat Mesenteric Vasculature

Overview

Journal J Smooth Muscle Res

Specialty Physiology

Date 2024 Nov 20

PMID 39567020

Authors

Muneaki Hidaka

Takayuki Matsumoto

Takayuki Nagano

Ryuichi Yamamoto

Naoko Tanaka-Totoribe

Affiliations

Soon will be listed here.

Abstract

Although naloxone is an antagonist of the opioid µ receptor, its effect on the peripheral sympathetic nerve function in the blood vessels has not yet been definitively elucidated. Therefore, we examined the effects of naloxone on vasoconstriction of the vascular smooth muscle of rats. Isolated rat mesenteric vascular-intestinal loop preparations were treated with either endogenous or exogenous α adrenoceptor agonists followed by prazosin, a selective antagonist of the α adrenoceptor, or naloxone, and noradrenaline overflow was measured. Vasoconstriction caused by peri-arterial nerve stimulation (PNS) and phenylephrine, an exogenous agonist of the α adrenoceptor, was abolished by prazosin. However, prazosin did not affect PNS-induced endogenous noradrenaline overflow. Naloxone did not affect either PNS-induced endogenous noradrenaline overflow or vasoconstriction. However, naloxone did inhibit phenylephrine-induced vasoconstriction. In addition, naloxone did not affect the angiotensin II-induced vasoconstriction. These results demonstrate that naloxone selectively inhibits vasoconstriction caused by phenylephrine, but not vasoconstriction caused by endogenous noradrenaline released from sympathetic nerve cells in the rat mesenteric vasculature.

References

Wenzel K, Wallukat G, Qadri F, Hubner N, Schulz H, Hummel O . Alpha1A-adrenergic receptor-directed autoimmunity induces left ventricular damage and diastolic dysfunction in rats. PLoS One. 2010; 5(2):e9409. PMC: 2827566. DOI: 10.1371/journal.pone.0009409. View

NGAI S, Berkowitz B, Yang J, Hempstead J, Spector S . Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. Anesthesiology. 1976; 44(5):398-401. DOI: 10.1097/00000542-197605000-00008. View

Marshall J . The effect of uptake by adrenergic nerve terminals on the sensitivity of arterial vessels to topically applied noradrenaline. Br J Pharmacol. 1977; 61(3):429-32. PMC: 1667900. DOI: 10.1111/j.1476-5381.1977.tb08436.x. View

Yamamoto R, Takasaki K, Nickols G . Purinergic vasoconstrictor component revealed by moderate cooling in the isolated mesenteric vasculature of Sprague-Dawley rats. J Pharmacol Exp Ther. 1992; 262(3):1133-8. View

Take H, Shibata K, Awaji T, Hirasawa A, Ikegaki I, Asano T . Vascular alpha1-adrenoceptor subtype selectivity and alpha1-blocker-induced orthostatic hypotension. Jpn J Pharmacol. 1998; 77(1):61-70. DOI: 10.1254/jjp.77.61. View

Gairola R, Gupta P, Pandley K . Antagonists of morphine-induced respiratory depression. A study in postoperative patients. Anaesthesia. 1980; 35(1):17-21. DOI: 10.1111/j.1365-2044.1980.tb03714.x. View

Yamamoto R, Cline Jr W . Release of endogenous NE from the mesenteric vasculature of WKY and SHR in response to PNS. J Pharmacol Exp Ther. 1987; 241(3):826-32. View

Westfall T . Neuroeffector mechanisms. Annu Rev Physiol. 1980; 42:383-97. DOI: 10.1146/annurev.ph.42.030180.002123. View

Bucher B, Corriu C, STOCLET J . Prejunctional opioid mu-receptors and adenosine A1-receptors on the sympathetic nerve endings of the rat tail artery interact with the alpha 2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 1992; 345(1):37-43. DOI: 10.1007/BF00175467. View

10.

Cohen R, COFFMAN J . Naloxone reversal of morphine-induced peripheral vasodilatation. Clin Pharmacol Ther. 1980; 28(4):541-4. DOI: 10.1038/clpt.1980.200. View

11.

Sasaki T, Kassell N, Turner D, Coester H . Comparison of the effect of naloxone on cerebral versus mesenteric arterial smooth muscle in feline and primate species. Stroke. 1984; 15(6):1025-8. DOI: 10.1161/01.str.15.6.1025. View

12.

Sasaki T, Kassell N, Turner D, Maixner W, Torner J, Coester H . Effects of naloxone on canine cerebral vascular smooth muscle. J Cereb Blood Flow Metab. 1984; 4(2):166-72. DOI: 10.1038/jcbfm.1984.24. View

13.

Yamamoto R, Cline Jr W . Effects of propranolol and yohimbine on periarterial nerve stimulation-induced release of endogenous norepinephrine from the mesenteric vasculature of Wistar Kyoto and spontaneously hypertensive rats. J Pharmacol Exp Ther. 1988; 244(3):905-11. View

14.

Gu H, Barron B, Gaugl J, Caffrey J . Dynorphin, naloxone, and overflow of norepinephrine during cardiac nerve stimulation in dogs. Am J Physiol. 1992; 263(1 Pt 2):H153-61. DOI: 10.1152/ajpheart.1992.263.1.H153. View

15.

Yamamoto R, Cline Jr W, Takasaki K . Reassessment of the blocking activity of prazosin at low and high concentrations on sympathetic neurotransmission in the isolated mesenteric vasculature of rats. J Auton Pharmacol. 1988; 8(4):303-9. DOI: 10.1111/j.1474-8673.1988.tb00573.x. View

16.

Burnstock G . Purinergic Signaling in the Cardiovascular System. Circ Res. 2017; 120(1):207-228. DOI: 10.1161/CIRCRESAHA.116.309726. View

17.

Komidori H, Yamamoto R, Nickols G, Takasaki K . Characterization of the isolated rat mesenteric vascular-intestinal loop preparation. J Pharmacol Toxicol Methods. 1992; 27(1):59-65. DOI: 10.1016/1056-8719(92)90022-s. View

18.

Shimamura K, Sekiguchi F, Matsuda K, Yamamoto K, Tanaka S, Sunano S . Membrane potential of mesenteric artery from carvedilol-treated spontaneously hypertensive rats. Eur J Pharmacol. 1998; 344(2-3):161-8. DOI: 10.1016/s0014-2999(97)01573-2. View

19.

Lynn R, Galinkin J . Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf. 2018; 9(1):63-88. PMC: 5753997. DOI: 10.1177/2042098617744161. View

20.

Furness J, Marshall J . Correlation of the directly observed responses of mesenteric vessles of the rat to nerve stimulation and noradrenaline with the distribution of adrenergic nerves. J Physiol. 1974; 239(1):75-88. PMC: 1330938. DOI: 10.1113/jphysiol.1974.sp010556. View